Scope Fluidics a biotechnological company registered on the New Connect stock exchange and the owner of two innovative medical diagnosis projects has started to work with Microfluidic ChipShop GmbH – a German laboratory chip manufacturer experienced in the microfluidic technologies,, (contract was signed by Curiosity Diagnostics, Scope Fluidics’ subsidiary).
The cooperation is aimed at designing the PCR|ONE panel, optimised from both the cost and the production technology perspectives. Simultaneously, Microfluidic ChipShop is working on the idea of PCR|ONE panel mass production, including the indispensable cost assessment required to achieve the planned production volume. This phase will last three months.
– According to the schedule, we are about to enter into an extremely significant stage of the PCR|ONE system development – preparation for the production of the first product series. Within the upcoming three months we will refine the details of the most important process in implementing the PCR | ONE system on the way to CE-IVD. Microfluidic ChipShop has many years of experience in the production of diagnostic systems for medical diagnostics – says Prof. Piotr Garstecki, cofounder, shareholder and CEO at Scope Fluidics. Soon we are planning to begin working with another partner, aiming to develop the device itself.
The PCR|ONE system is expected to enter the commercial market in the second half of 2020. At the same time we expect the EU certification. We signed a contract with Clarified International in mid 2018, a US consultancy firm to assist us in finding a buyer for the system. The commercialisation idea of the project is to the company including the intellectual property, product development and device registration packages. The transaction will definitely influence the dividend potential. The Scope Fluidics business model considers payment of dividend worth at least half the profit generated upon selling the project.
